Folomeev M Iu
Ter Arkh. 1986;58(7):112-4.
A controlled trial of the androgenic drug Sustanon-250 was conducted in 9 male patients with exacerbation of systemic lupus erythematosus (SLE). The drug was administered intramuscularly once a week for 4 weeks. The therapy resulted in changes of the initially disturbed levels of sex hormones: the initially lowered levels of testosterone increased significantly by the end of the study (p less than 0.01), the level of serum estradiol and the estrogenic/androgenic ratio returned to normal. A decrease in the values of ESR,L2 and gamma globulins, G and A immunoglobulins, a-DNA, ANF and CRP titers was noted. The amount of T-lymphocytes increased. Two patients were not given corticosteroid and cytotoxic drugs, a dose of drugs for 1 patient was not raised and for 3 patients it was lowered. Over the period of the study skin symptoms, the degree of expression of lymphadenopathy, polyarthritis and Raynaud's syndrome decreased. The drug produced an insignificant effect on the serous membranes, heart and kidneys. The first experience in the use of androgens in men indicated pathogenetic influence of such drugs on SLE.
对9例系统性红斑狼疮（SLE）病情加重的男性患者进行了雄激素药物复方睾酮庚酸酯-250的对照试验。该药物每周肌肉注射1次，共注射4周。治疗导致了最初紊乱的性激素水平发生变化：研究结束时，最初降低的睾酮水平显著升高（p<0.01），血清雌二醇水平以及雌激素/雄激素比值恢复正常。观察到血沉、L2和γ球蛋白、G和A免疫球蛋白、抗双链DNA、抗核因子和C反应蛋白滴度值降低。T淋巴细胞数量增加。2例患者未使用皮质类固醇和细胞毒性药物，1例患者的药物剂量未增加，3例患者的药物剂量降低。在研究期间，皮肤症状、淋巴结病、多关节炎和雷诺综合征的表现程度减轻。该药物对浆膜、心脏和肾脏产生的影响不显著。男性使用雄激素的首次经验表明此类药物对SLE有致病影响。
